JUPW vs. SABS, POCI, PXDT, PMN, SNSE, ACHL, MRKR, ESLA, INKT, and AWH
Should you be buying Jupiter Wellness stock or one of its competitors? The main competitors of Jupiter Wellness include SAB Biotherapeutics (SABS), Precision Optics (POCI), Pixie Dust Technologies (PXDT), ProMIS Neurosciences (PMN), Sensei Biotherapeutics (SNSE), Achilles Therapeutics (ACHL), Marker Therapeutics (MRKR), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), and Aspira Women's Health (AWH). These companies are all part of the "medical" sector.
SAB Biotherapeutics (NASDAQ:SABS) and Jupiter Wellness (NASDAQ:JUPW) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
Jupiter Wellness has higher revenue and earnings than SAB Biotherapeutics.
In the previous week, Jupiter Wellness had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Jupiter Wellness and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.25 beat Jupiter Wellness' score of 0.00 indicating that Jupiter Wellness is being referred to more favorably in the news media.
SAB Biotherapeutics received 17 more outperform votes than Jupiter Wellness when rated by MarketBeat users. Likewise, 73.91% of users gave SAB Biotherapeutics an outperform vote while only 0.00% of users gave Jupiter Wellness an outperform vote.
Jupiter Wellness has a net margin of -210.13% compared to Jupiter Wellness' net margin of -1,884.10%. Jupiter Wellness' return on equity of -144.66% beat SAB Biotherapeutics' return on equity.
7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 15.6% of Jupiter Wellness shares are owned by institutional investors. 26.0% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 32.9% of Jupiter Wellness shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
SAB Biotherapeutics currently has a consensus price target of $15.50, indicating a potential upside of 327.00%. Given Jupiter Wellness' higher possible upside, equities analysts plainly believe SAB Biotherapeutics is more favorable than Jupiter Wellness.
SAB Biotherapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Jupiter Wellness has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
Summary
SAB Biotherapeutics beats Jupiter Wellness on 8 of the 15 factors compared between the two stocks.
Get Jupiter Wellness News Delivered to You Automatically
Sign up to receive the latest news and ratings for JUPW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JUPW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jupiter Wellness Competitors List
Related Companies and Tools
